The Hidden Cost of Technical Debt in Medical Device Development

Why engineering shortcuts today become regulatory crises tomorrow

The Problem Everyone Has, But Few Name

Every engineering team under schedule pressure makes tradeoffs. Document it later. Close the risk gap after the milestone. Patch the test protocol after verification. These decisions accumulate quietly until a product launch, an FDA inspection, or a post-market complaint forces a reckoning that costs orders of magnitude more than the original shortcut.

Software developers have been talking about technical debt for decades. Ward Cunningham coined the concept in 1992¹ to describe the long-term cost of choosing a fast solution over the right one. The idea took hold because it gave engineering teams a language for something they already felt but could not articulate to leadership.

Hardware-heavy medical device development carries the same dynamic. The difference is that the consequences do not slow your next release cycle. They show up as 483 observations, failed safety evaluations, delayed 510(k) submissions, and CAPA spirals that can run for years.

In fiscal year 2024, the FDA issued 47 warning letters to medical device companies. That represents a 96% increase over the 24 issued in FY2023.² The enforcement environment has tightened considerably. As of February 2, 2026, the FDA’s new Quality Management System Regulation (QMSR) replaced the Quality System Inspection Technique (QSIT) with a risk-based inspection approach that reaches further into an organization than its predecessor.³ The FDA held a dedicated town hall on the updated inspection program in April 2026 to clarify expectations across industry.⁶

Inspectors are now tracing post-market complaints and field performance issues all the way back to design input ambiguity.⁴ Technical debt that was tolerable under the old inspection model is becoming visible in new ways.

So what does technical debt actually look like in a medical device context, and why is it so hard to catch before it compounds?

How It Compounds

Defining Technical Debt in the Medical Device Context

In software, technical debt is often easy to locate. Code comments that say // fix this later are a reasonable proxy. In hardware-intensive medical device development, it’s considerably more diffuse.

Technical debt accumulates across the full development ecosystem: design controls that do not accurately reflect actual design decisions, risk analyses with gaps that only surface during external safety evaluations, requirements documentation written after the fact rather than before it, SOPs written for a different type of organization that have not caught up to the actual product, and business systems that were never designed to talk to each other.

The last category tends to be the most underestimated. When CAD, QMS, PLM, and ERP operate as silos, every revision cycle is an opportunity for divergence. A bill of materials updated in CAD that does not flow automatically through to the quality or enterprise systems creates documentation discrepancies that accumulate invisibly until a V&V effort, a supplier audit, or an FDA inspector surfaces them.

What makes medical device technical debt distinctly different from its software counterpart is that the debt collector is not a frustrated developer or a sprint retrospective. It is a certification lab, an FDA inspector, or a post-market complaint that traces back to a design input that was never formally captured. The interest compounds in regulatory time, not sprint time.

Dimension‍ ‍Software Technical Debt‍ ‍Medical Device Technical Debt

Where it hides ‍ ‍Code comments, test failures, Design controls, risk files, SOPs, disconnected

slow builds—visible to developers business systems—invisible until forced

in daily work to the surface

Who collects it‍ ‍The next sprint team—slower A certification lab, an FDA inspector, or a

velocity, mounting bug counts, post-market complaint tracing back

technical frustration to a design input never formally captured

When it surfaces‍ ‍Sprint retrospectives, velocity 510(k) submission, third-party safety evaluation,

decline, architecture reviews FDA 483 observation, CAPA spiral

Time scale of‍ ‍Sprint time—weeks to months‍ ‍Regulatory time—months to years; remediation

interest‍ ‍cost compounds with each phase crossed

Most insidious Undocumented architectural Siloed business systems: CAD, QMS, PLM, ERP

form decisions accumulating across that do not communicate—every revision

‍ ‍releases cycle is a divergence opportunity

What the Differentiation Factor Actually Looks Like

Most commentary on medical device technical debt comes from one of two vantage points: engineering or regulatory. Engineers describe it in terms of undocumented design decisions and integration gaps. Regulatory professionals describe it in terms of missing DHF records and CAPA overload.

What rarely gets discussed is what the problem looks like when you are responsible for both simultaneously.

In a decade leading engineering and quality and regulatory functions at the same time on one of the most complex Class II medical devices ever FDA-cleared, a capital system spanning eight technology domains and assembled from components supplied by manufacturers across multiple continents, the relationship between the two sides of technical debt became clear in ways that are difficult to develop any other way.

A design decision made under schedule pressure in week three affects a risk analysis in week thirty. A requirements gap in a supplier-furnished assembly does not surface until a third-party safety evaluation reviews all applicable clauses across four to five core medical device standards. An SOP that no longer matches how work is actually done becomes a 483 observation three years after it was written. None of these are theoretical. All of them are expensive.

The system comprised roughly 20 complex assemblies. The majority were designed by external suppliers, some with mature medical device design control experience and some without any. The internal engineering team was responsible for integrating all of it, including filling regulatory gaps wherever suppliers fell short, particularly across multiple layers of risk analysis.

Prior to a unified engineering and quality/regulatory leadership structure being in place, the quality and regulatory function had turned over multiple times. Each transition brought a new perspective shaped by high-volume, low-complexity device environments. Applied to a very low-volume, highly complex system, those frameworks created two compounding problems: SOPs that had grown unnecessarily complicated from successive authorship layers, and key regulatory terms that had drifted from their formal definitions in practice.

Design Inputs were the clearest example. The term had evolved to mean something the organization had constructed from context rather than from regulation. By the time a systems engineering function was established to bring formal structure to requirements management, assemblies had already been procured based on informal user requirements. The catch-up effort required to reconstruct proper design input documentation across all 20 assemblies, traceable to roughly 50 applicable international standards with hundreds of clauses each, was significant.

That rework was a prerequisite for the 510(k) submission, which made it unavoidable. The real cost came during a full safety and risk evaluation by an accredited third-party certification laboratory. That evaluation reviews all applicable clauses across the core medical device standards, starting with IEC 60601-1, and verifies that they were captured in Design Inputs, that appropriate risk analyses were completed across hazard analysis, DFMEA, PFMEA, and UFMEA, and that identified risks were actually mitigated through design or documented analysis.

On numerous occasions, new engineering analyses had to be commissioned to justify mitigation of safety requirements that had not been captured in the original Design Inputs. What should have been a focused evaluation became a year-long program. The contrast with a handful of standalone assemblies that came with their own 510(k) clearances and complete documentation was instructive. The lab’s review of those assemblies was straightforward. Everything else required significant reconstruction work.

The Disconnected Systems Problem

In environments where quality systems have been built in-house rather than on purpose-built regulatory platforms, a predictable set of gaps tends to emerge. The system functions as a document repository rather than an integrated quality infrastructure. CAD is siloed from quality records. Bills of materials require manual transfer between design and manufacturing systems. Design revision control is applied inconsistently across assemblies.

The practical effect is that every engineering change becomes a manual coordination exercise across systems that were never designed to talk to each other.

System Gap‍ ‍What Happens‍ ‍What It Costs

CAD ↔ QMS Design revision in CAD not reflected Documentation discrepancy: the device built

in quality records does not match the device described in the DHF

PLM ↔ QMS‍ ‍Bill of materials updated in PLM without Change control gap; inspection observation when

triggering quality review BOM in quality system diverges from manufacturing

reality

CAD ↔ ERP Part numbers diverge between Supplier audit findings; component

design and procurement traceability failures under QMSR

QMS →Design‍ ‍Requirements management Design inputs written after the fact; cannot

Inputs‍ ‍disconnected from formal demonstrate traceability forward into

QMS workflows verification or backward from complaints

All systems Manual transfer at every revision Every engineering change is a manual coordination

cycle across non-integrated exercise—and a potential divergence point

systems invisible until a V&V effort or FDA inspector

‍ ‍surfaces it

The design input documentation gaps described above compounded directly into verification and validation. Because the starting framework was misaligned, the downstream effect through safety, risk, V&V, and ultimately 510(k) documentation required an extensive manual correction effort across spreadsheets and working documents.

The transition to an enterprise-grade QMS/PLM/MES platform structured around the regulations addressed many of the immediate deficiencies. A standalone ERP system was added as well. But the broader integration architecture connecting all systems from design through manufacturing and accounting took considerable time to fully realize, and the window during which multiple major workstreams ran in parallel created significant organizational burden.

Running a cleared device through post-market surveillance, developing a second system for an international customer with specific TGA regulatory requirements, standing up new business systems, and remediating inspection observations at the same time is a meaningful stress test for any organization.

The Executive Conversation

In most organizations, the business case for investing in technical debt reduction does not gain real traction until a regulatory event makes the cost tangible. Internal risk arguments rarely move as quickly as external inspection results.

What tends to work is framing the conversation around two numbers: the cost of identifying and closing a gap during an internal audit or gap assessment, and the cost of closing the same gap after an FDA inspection observation, a 510(k) rejection, or a third-party safety evaluation. Those are very different numbers, and leadership responds to the comparison more readily than to abstract compliance language.

Trigger‍ ‍Who Initiates‍ ‍ Direct Costs‍ ‍Timeline Impact‍ ‍Strategic Consequence

Internal gap‍ ‍Self-initiated; Consulting Typically weeks to Findings addressed

assessment‍ ‍voluntary; engagement, months; fully manageable proactively;

controlled staff time, on own timeline remediation sequenced

scope documentation against product

effort schedule

Post-510(k)‍ ‍FDA-initiated; Submission fees 6–18 months additional Competitive window

rejection triggered by (re-filing), clearance delay typical lost; clinical

submission consultant costs, partnerships at risk

review delayed revenue

Post-FDA FDA-initiated; Remediation Response in 15 business Warning letter risk if

483 inspection finding, consultant costs, days; remediation response inadequate;

observation formal response internal quality may run 12–24 permanently public

required team diversion, months record

legal review

Post-third Notified body Additional Year-long programs not 510(k) submission

-party or accredited engineering unusual at this scale blocked until resolved;

safety lab finding analysis, re-test of complexity entire program schedule

evaluation fees, lab time impact

Post-market Field-triggered; CAPA initiation, Indeterminate— Compounding quality

complaint complaint MDR evaluation, depends on scope system burden;

tracing to investigation potential recall of underlying gap FDA visibility into

DHF gap opens design assessment design control history

history

The organizations that handle technical debt most effectively are the ones that conduct structured gap assessments before they are forced to. They use the assessment output to build a prioritized remediation roadmap, assign ownership, and present it to leadership as a risk reduction investment rather than a compliance line item. That framing changes the conversation.

The QMSR transition that took effect February 2, 2026 is a practical entry point for exactly this kind of conversation. Companies that have not yet conducted a formal QMSR gap assessment have a legitimate and time-bound reason to do so. The assessment, done well, will surface technical debt. The remediation plan that follows is the business case.

What to Do About It

Connecting the Dots Before the FDA Does

The QMSR inspection framework has extended the FDA’s reach in specific ways that make historical workarounds more visible. Under the new risk-based approach, inspectors are no longer constrained by the QSIT subsystem structure.³ The agency can now review management reviews, internal quality audits, and supplier audit reports during inspections.⁵ Post-market signals including complaint spikes and MDRs are being traced back to design input gaps.⁴ The connection between historical documentation choices and current enforcement outcomes is tighter than it has ever been.

From practical experience, the most effective interventions happen in a specific sequence:

Priority Action‍ Where to Look‍ ‍ What to Do‍ ‍Why It Matters Under QMSR

Start with‍ Design Inputs Review every design input for Design inputs are the regulatory

Requirements completeness, traceability to load-bearing element of the DHF.

applicable standards, and Gaps propagate forward into

alignment with what was safety evaluation, V&V,

actually designed— and 510(k) review—and backward

not what was intended from complaints under QMSR

Audit Risk‍ ‍Hazard Analysis, Compare risk files against the Gaps found during external safety

Documentation ‍ ‍DFMEA, actual design state. Identify evaluation cost orders of magnitude

PFMEA, analyses performed against more than gaps found during

‍ ‍UFMEA early design assumptions internal design review

that no longer reflect

the built device

Assess‍ ‍CAD → PLM → Map every revision workflow: Every non-integrated handoff

Business‍ ‍QMS → ERP where does data transfer is a potential divergence point

System‍ ‍require manual steps? accumulating invisibly until

Integration Where can CAD diverge an inspector or V&V

from QMS without effort forces it to the surface

triggering a control?

Simplify‍ ‍Quality Compare each SOP against A procedure complex enough

SOPs‍ ‍Management‍ ‍how work is actually performed. that it cannot be consistently

to Match‍ ‍System Flag procedures that have followed provides no compliance

Operations accumulated complexity protection—and actively

from successive authorship creates inspection risk

layers

Have the Leadership / Translate technical debt into The QMSR transition is a

Executive Finance two numbers: cost of closing time-bound, externally credible

Conversation a gap internally vs. cost of reason to conduct a gap

closing it after a 483 assessment now. Frame

observation, 510(k) rejection, remediation as a risk reduction

or safety evaluation finding investment, not a compliance

line item

The QMSR transition provides a time-bound and externally credible reason to conduct that gap assessment now. Companies that use the process to identify and quantify their technical debt have a natural entry point for the business case.

If your organization is navigating a QMSR transition, preparing for an upcoming FDA inspection, or working through business systems that were not designed to function as an integrated whole, the frameworks developed through direct operational experience in exactly these environments may be worth a conversation.

Feel free to connect or reach out directly.

Dan Raymond  ·  Founder, Springboard Solutions LLC

603-475-6490  ·  draymond@springboardsolutionsllc.com  ·  springboardsolutionsllc.com

#MedicalDevices #QMSR #SpringboardSolutions

References

1 Cunningham, W. (1992). The WyCash Portfolio Management System. Addendum to the Proceedings of OOPSLA 1992. ACM. http://c2.com/doc/oopsla92.html

2 FDA Warning Letters for Medical Devices: Complete Guide 2025. Complizen.ai. September 2025. https://www.complizen.ai/post/fda-warning-letters-for-medical-devices-complete-guide-2025

3 Ropes & Gray LLP. (February 2026). A QMSR State of Mind: FDA Adopts New Inspection Approach for Medical Devices as Quality Management System Regulation Takes Effect. https://www.ropesgray.com/en/insights/alerts/2026/02/a-qmsr-state-of-mind-fda-adopts-new-inspection-approach-for-medical-devices

4 Hogan Lovells. (September 2025). FDA Medical Device Inspections in 2025: What We’re Seeing, What We Expected, and Why You Need the Right Expertise Now. https://www.hoganlovells.com/en/publications/fda-medical-device-inspections-in-2025

5 U.S. Food and Drug Administration. (February 2026). Quality Management System Regulation (QMSR): Frequently Asked Questions. https://www.fda.gov/medical-devices/quality-management-system-regulation-qmsr/quality-management-system-regulation-frequently-asked-questions

6 U.S. Food and Drug Administration. (April 2026). Town Hall: QMSR Medical Device Risk-Based Inspections. https://www.fda.gov/medical-devices/medical-devices-news-and-events/town-hall-fdas-quality-management-system-regulation-qmsr-medical-device-risk-based-inspections